Regeneron Says Newly Approved Drug Shows Sustained Efficacy In Halting Rogue Bone Growth
Regeneron's Pasatru shows sustained efficacy in halting new bone growth and reducing flare-ups in adults with FOP in an 84-week trial.
Stocks · News reference
Regeneron Pharmaceuticals Announces Data From Its Phase 3 OPTIMA Study Of Pasatru To Treat Fibrodysplasia Ossificans Progressiva Shows Efficacy In Stopping New Bone Growth; Trial Meets Primary Endpoint By Reducing 90% New Heterotopic Ossification Lesions
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive 84-week results from the Phase 3 OPTIMA trial evaluating Pasatru™ (garetosmab-grts) in adults with fibrodysplasia ossificans progressiva (FOP).
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Bayer Seeks Kerendia Label Expansion in Non-Diabetic CKD
Bayer announced FDA acceptance of a supplemental new drug application for Kerendia (finerenone) to treat chronic kidney disease in non-diabetic patients. The approval is based on positive phase III FIND-CKD trial data showing the drug significantly delayed kidney disease progression and reduced cardiovascular-kidney events. This expansion broadens Kerendia's addressable market and strengthens Bayer's cardiovascular and renal portfolio, with the drug already approved for diabetic CKD and heart failure in multiple markets.
RBC Capital Maintains Sector Perform on Regeneron Pharmaceuticals, Raises Price Target to $810
RBC Capital analyst Brian Abrahams maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Sector Perform and raises the price target from $737 to $810.